Heterologous Prime/Boost Immunization with p53-based Vaccines Combined with Toll-Like Receptor Stimulation Enhances Tumor Regression

The p53 gene product is overexpressed in ~50% of cancers, making it an ideal target for cancer immunotherapy. We previously demonstrated that a modified vaccinia Ankara (MVA) vaccine expressing human p53 (MVA-p53) was moderately active when given as a homologous prime/boost in a human p53 knock in (...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Ishizaki, Hidenobu, Song, Guang-Yun, Srivastava, Tumul, Carroll, Kyla Driscoll, Shahabi, Vafa, Manuel, Edwin R., Diamond, Don J., Ellenhorn, Joshua D.I.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3523364/
https://ncbi.nlm.nih.gov/pubmed/20551836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0b013e3181e032c6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi